How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,896 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments. (Abstract)

Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments. Psoriasis is a chronic dermatologic disease affecting 2% of the general population. Tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a newly defined member of the TNF family. Increased serum levels of TWEAK were reported in inflammatory diseases. The relationship between serum (...) TWEAK levels and severity of psoriasis has not yet been proven. Our aim was to clarify the change in serum TWEAK levels in response to conventional and anti-TNF treatments.Blood samples were collected from 103 moderate or severe chronic plaque psoriasis patients with or without arthritis who were referred to the Department of Dermatology, Istanbul University Cerrahpasa Medical Faculty between the years 2016 and 2018. Psoriasis Area and Severity Index (PASI) scores were calculated, and serum TWEAK

2019 International Journal of Dermatology

82. Quality of Life in Psoriasis Vulgaris: Use of the ItchyQoL Question-naire in a Secukinumab Phase III Trial in Patients with Psoriasis Vulgaris. Full Text available with Trip Pro

Quality of Life in Psoriasis Vulgaris: Use of the ItchyQoL Question-naire in a Secukinumab Phase III Trial in Patients with Psoriasis Vulgaris. Chronic pruritus is a bothersome symptom in psoriasis vulgaris and can profoundly reduce quality of life (QoL). In this exploratory analysis of the PSORITUS study, the impact of pruritus on QoL in 130 subjects with moderate-to-severe psoriasis was assessed using the ItchyQoL questionnaire. The majority of patients (n = 127) had to scratch their itchy (...) questionnaire as a validated tool responsive to treatment for detailed insights into chronic pruritus in patients with psoriasis.

2019 Acta Dermato-Venereologica

83. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Full Text available with Trip Pro

Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). The 'treat to target' paradigm improves outcomes and reduces costs in chronic disease management but is not yet established in psoriasis.To identify treatment targets in psoriasis using two common measures of disease activity: Psoriasis Area and Severity Index (PASI) and Physician's (...) Global Assessment (PGA).Data from a multicentre longitudinal U.K. cohort of patients with psoriasis receiving systemic or biologic therapies (British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) were used to identify absolute PASI thresholds for 90% (PASI 90) and 75% (PASI 75) improvements in baseline disease activity, using receiver operating characteristic curves. The relationship between PGA (clear, almost clear, mild, moderate, moderate-severe, severe) and PASI

2019 British Journal of Dermatology

84. Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis. (Abstract)

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis. Three biotherapies - etanercept, adalimumab and ustekinumab - are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. However, biological drug survival impacts long-term performance in real-life settings.The objective of this study was to evaluate the survival (...) rates of biological therapies in children with psoriasis in real-life conditions. Secondary objectives were to evaluate the factors associated with the choice of the biological therapy and to report severe adverse events.This study was an observational retrospective study. Data were extracted from the clinical records of 134 children. Kaplan-Meier estimates were used to analyse drug survival overall and in subgroups of plaque psoriasis, bio-naïve and non-naïve patients.We analysed 184 treatment

2019 Journal of the European Academy of Dermatology and Venereology

85. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Full Text available with Trip Pro

A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Herpes zoster (HZ) incidence is linked to immunosuppression. Patients with psoriasis or psoriatic arthritis (PsA) on systemic therapy might be at an increased risk for HZ.To assess HZ risk in patients with psoriasis and PsA by systemic treatment and provide (...) recommendations regarding HZ vaccination.A systematic literature search was performed for HZ in patients with psoriasis and PsA. HZ vaccination guidelines were reviewed, and the medical board of the National Psoriasis Foundation made consensus recommendations in psoriasis and PsA patients using graded evidence.In total, 41 studies met inclusion criteria. Systemic corticosteroids (strong, 1), tofacitinib (strong, 1), and combination therapy with biologic and conventional synthetic disease-modifying

2019 Journal of American Academy of Dermatology

86. Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. (Abstract)

Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. Biologics are potent immunomodulatory drugs, whose application in the treatment of psoriasis has shown extremely good therapeutic results and a satisfactory safety profile. The administration of these agents in special cases, such as in patients with HIV infection, previous malignancy, unclear vaccination status as well as children

2019 International Journal of Dermatology

87. Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. Full Text available with Trip Pro

Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. Psoriasis is a chronic skin disease associated with considerable physical and psychological co-morbidities. Stress and emotional disturbances have been implicated in both triggering the onset and exacerbation of psoriasis. In order to determine the level of perceived stress and mood alterations in patients (...) with psoriasis and their association with disease severity, 300 individuals completed diverse validated questionnaires assessing stress and psychological mood. Evaluation of perception of disease was also measured. A significant association between psoriasis severity and mood, emotional disturbances and an impact on assessments of the quality of life were observed. Particularly, Montgomery-Asberg Depression Rating Scale, Hamilton Rating Scale and Hospital Anxiety and Depression Scale for Depression detected

2019 Acta Dermato-Venereologica

88. Institute for Clinical and Economic Review (ICER) Psoriasis Update 2018: What it means for dermatologists treating moderate-to-severe plaque psoriasis. (Abstract)

Institute for Clinical and Economic Review (ICER) Psoriasis Update 2018: What it means for dermatologists treating moderate-to-severe plaque psoriasis. This paper aims to summarize the key findings of the updated report issued in August 2018 by the Institute of Clinical and Economic Review (ICER) regarding the clinical efficacy and budget impact of various immunomodulators.This paper specifically focuses on the inclusion of two new biologics, guselkumab and certolizumab in the context (...) for more consensus guidelines in the use of biologics in the treatment of psoriasis, and perhaps consideration of costs within these guidelines.

2019 Journal of Dermatological Treatment

89. Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment. Full Text available with Trip Pro

Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment. In the U.S., black patients are less likely than whites to receive biologic treatment for their psoriasis. We conducted a qualitative freelisting study to identify patient-generated factors that may explain this apparent racial disparity in psoriasis treatment by comparing the perceptions of biologics and other psoriasis therapies between white and black adults with psoriasis (...) . Participants included 68 white and black adults with moderate to severe psoriasis who had and had not received biologic treatment. Each participant was asked to list words in response to verbal probes querying five psoriasis treatments: self-injectable biologics, infliximab, methotrexate, apremilast, and phototherapy. Salience scores indicating the relative importance of each word were calculated, and salient words were compared across each race-treatment group. Participants who had experience

2019 Journal of Investigative Dermatology

90. Ocular findings in patients with psoriasis: Is it related to the side effects of treatment or to psoriasis itself? A case-control study. (Abstract)

Ocular findings in patients with psoriasis: Is it related to the side effects of treatment or to psoriasis itself? A case-control study. To assess ocular abnormalities in psoriatic patients (new-cases versus patients under treatment) in comparison with healthy controls.A total of 200 psoriatic patients and 100 healthy controls were enrolled in this prospective, observational study. The demographic data of the individuals were recorded. Dermatological and ophthalmologic examinations were (...) the groups. Although no significant differences were found between the ocular findings of new cases and patients under treatment, ocular findings in cases under treatment were associated with the type of treatment and more frequent in those treated with methotrexate, followed by acitretin and biologic drugs.Ocular surface problems in psoriatic patients are more common than previously thought; in addition to the role of treatment modalities, psoriasis itself and a probable systemic inflammation may play

2019 Journal of Dermatological Treatment

91. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. (Abstract)

Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. Nail involvement in psoriasis is common, and the severity of it does not always parallel the intensity of cutaneous disease. We created a consensus group, of which the aim was to provide practical recommendations for the treatment of nail psoriasis in patients without skin psoriasis, or with mild skin lesions (...) with no indication for a systemic treatment. This collaborative process was conducted by an international panel of dermatologists with special expertise in nail disorders, using a formal consensus methodology. During this process, the panel strived to establish an agreement regarding the definition of nail psoriasis, the severity of nail psoriasis, and treatment response. Treatment recommendations are provided regarding nail psoriasis severity and matrix or bed involvement. "Few-nail" disease was considered

2019 Journal of American Academy of Dermatology

92. Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council. Full Text available with Trip Pro

Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council. Psoriasis in children can be a challenging diagnosis: the clinical presentation is often more subtle, may occur in covered sites and can be an unexpected diagnosis as psoriasis if often thought to occur at older ages. Poor recognition and delayed diagnosis of psoriasis in children can lead to inadequate treatment and lack of monitoring

2019 British Journal of Dermatology

93. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. Full Text available with Trip Pro

US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. To examine the real-world effectiveness of secukinumab with regard to clinical and patient-reported outcomes (PROs) from enrollment to a 6-month follow-up visit in patients with psoriasis in the Corrona Psoriasis Registry.Eligible patients aged ≥ 18 years who initiated secukinumab at enrollment in the Corrona Psoriasis Registry and had a 6-month follow-up visit

2019 Journal of Dermatological Treatment

94. Long-term maintenance of secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. (Abstract)

Long-term maintenance of secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. There is limited data regarding the long-term persistence of biological therapy in patients with psoriasis. In particular, reasons of secukinumab discontinuation have not been thoroughly investigated.To better ascertain the real life maintenance of secukinumab in psoriasis, we conducted a retrospective study to evaluate the incidence, causes and factors of secukinumab (...) discontinuation in patients with psoriasis.All patients treated with secukinumab for psoriasis in the dermatology department of Toulouse, France, between September 2011 and June 2017, were included.Among 91 patients included; 22 (24, 2%) patients discontinued secukinumab. In 14 (15%) patients, the discontinuation was due to loss of efficacy. Two patients stopped treatment because of a desire for pregnancy, five patients due to the occurrence of adverse events. A longer disease duration (p = 0,01

2019 Clinical & Experimental Dermatology

95. Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. (Abstract)

Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. Background: Psoriasis is a chronic inflammatory skin disease. Objective: To establish content validity and assess psychometric properties of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis (Ps). Methods: The PSS is an eight-item patient-completed questionnaire assessing symptoms (itch, pain, stinging, burning), signs (redness

2019 Journal of Dermatological Treatment

96. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. Full Text available with Trip Pro

Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. This analysis examined the association between psoriasis severity, assessed by body surface area (BSA) and the Investigator's Global Assessment (IGA; previously used only in clinical trials), and patient-reported outcomes (PROs) in a real-world setting.Cross-sectional analysis within the Corrona Psoriasis (...) Registry, an independent, prospective registry.70 dermatology practices in the USA.1529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by 31 May 2016.Psoriasis severity was assessed by percentage of affected BSA (mild (0%-5%), moderate (>5%-10%), severe (>10%-15%), very severe (>15%)) and IGA scores (clear/almost clear (0-1), mild (2), moderate (3), severe (4)). PROs (pain, itch, fatigue; Dermatology Life Quality Index [DLQI]; EuroQoL Visual

2019 BMJ open

97. [Secukinumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V (new scientific findings)]

[Secukinumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V (new scientific findings)] Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche erkenntnisse); dossierbewertung [Secukinumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V (new scientific findings)] Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche erkenntnisse); dossierbewertung [Secukinumab (plaque (...) psoriasis) - benefit assessment according to §35a Social Code Book V (new scientific findings)] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue

2017 Health Technology Assessment (HTA) Database.

98. [Ixekizumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V]

[Ixekizumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V] Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07 [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07 [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und (...) Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07. [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Cologne

2017 Health Technology Assessment (HTA) Database.

99. [Secukinumab (plaque psoriasis) - addendum to Commission A17-08]

[Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31 [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31 [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31. [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 529. 2017 Final publication URL Indexing Status Subject indexing

2017 Health Technology Assessment (HTA) Database.

100. [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07]

[Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30 [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30 [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30. [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 528. 2017 Final publication URL Indexing Status Subject indexing assigned

2017 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>